Testimonials
Billionaires including Elon Musk and Michael Rubin of Fanatics have sung the praises of GLP-1 drugs including Wegovy and Ozempic for weight loss. Here are a few resources to understand the trends and what manage care pharmacists need to know.
It’s crucial that MCPs are armed with the tools they need to ensure patients get the medications they need at a cost they can afford—and that starts with you.
AMCP 2024 AAO Report
AMCP's feature annual report explores how professionals in managed care pharmacy work diligently to facilitate appropriate access to prescription treatments while remaining mindful of rising costs. It discusses key areas of focus such as pharmacy benefit design, formulary management, clinical programs, quality, safety and promoting affordability of medicines.
AMCP eModel is the ultimate tool for communication of health economic models and value evidence. Find out more about this tech partnership and this health economic modeling platform to support the exchange of clinical and economic information between manufacturers and payers.
AMCP partners with FormularyDecisions to enhance information sharing and formulary decision-making by creating a platform for current, credible, and compliant information exchange between life science companies and active, qualified healthcare decision-makers.
Meetings Proceedings & Findings
From the AMCP Policy Digest, AMCP's policies regarding drug naming issues.
From the AMCP Policy Digest, AMCP's policies regarding patient confidentiality.
From the AMCP Policy Digest, AMCP's policies regarding health information and automation technology.
From the AMCP Policy Digest, AMCP's policies regarding workforce issues.
Recognizing the widespread and devastating nature of the opioid crisis, AMCP formed the Addiction Treatment Advisory Group in 2015 based on the recommendation from the AMCP Partnership Forum, Breaking the Link between Pain Management and Opioid Use Disorder.
AMCP CEO Blog: We live in an interconnected world where the marketplace for all things is global. But we must also make sure the global system works for the benefit of the patients we serve. That includes taking steps to ensure the long-term stability and integrity of our critical pharmaceutical supply chain.
The purpose of outcomes research per the Patient Centered Outcomes Research Institute (PCORI) is to assist patients, clinicians, purchasers and policy makers in making informed health decisions by advancing quality and relevance of evidence. The Agency for Healthcare Research and Quality (AHRQ) defines the purpose of outcomes research as a tool to provide evidence about benefits, risks, and results of treatments so clinicians and patients can make more informed decisions.
Health plans, employers and government-sponsored health care programs are focusing their attention on optimizing patient outcomes through the use of medications that have established evidence of efficacy and safety, while providing the highest value.
Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.
Congress passed the Health Insurance Portability and Accountability Act (HIPAA) in 1996. Within that Act are privacy provisions with which covered entities (including all health plans, health care providers and health care clearinghouses [e.g. PBMs] that transmit any health information in electronic form must comply. HIPAA rules provide guidance to covered entities about how to comply with the Act.
The purpose of this paper is to explain how managed care organizations (MCOs) are able to secure lower drug prices from pharmaceutical manufacturers as part of an effort to control drug expenditures.
Over the past several years, the introduction, utilization and cost share of specialty pharmacy products has been increasing at a rate substantially greater than that of other pharmaceuticals. This paper examines the characteristics of specialty pharmaceuticals; the growth of new expertise to handle and manage these pharmaceuticals; and the needs these products create for patients, health plans and practitioners.
